Based on a policy of stable dividends to shareholders, the company resolved an interim dividend of 20 yen per share with record date September 2026 and payment date November 30, 2026. The same amount is planned for the interim dividend for the fiscal year ending March 2027. Total dividends amount to 832 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2395","jir_company_name":"Shin Nippon Biomedical Laboratories, Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/2395-20261110-04.pdf","jir_short_summary":"Based on a policy of stable dividends to shareholders, the company resolved an interim dividend of 20 yen per share with record date September 2026 and payment date November 30, 2026. The same amount is planned for the interim dividend for the fiscal year ending March 2027. Total dividends amount to 832 million yen.","jir_summary":"### Dividend Policy and This Interim Dividend\nThe Company recognizes stable returns to shareholders as an important management policy, and determines dividends considering fundamental earning power and cash flow with a consolidated dividend payout ratio target of 30\u201340%. For this interim dividend with record date September 2026, we have decided on 20 yen per share, with total dividends of 832 million yen and payment date of 2026-11-30.\n\n### Outlook and Annual Dividend Breakdown\nThe annual dividend breakdown is assumed to be 30 yen at the end of Q2 and 20 yen at year-end (total 50 yen). The interim dividend for the fiscal year ending March 2027 is also planned at 20 yen, with a year-end dividend of 50 yen, and the full-year outlook is 20 yen\/20 yen\/50 yen.","jir_financial_highlights":"Dividend per share: 20 yen00 sen (Same as prior period)\nTotal dividends: 832 million yen (Same as previous forecast and prior period)\nPayment date: 2026-11-30 (\u2015)","jir_category":"","jir_hashtags":"#UnaffectedByShareBuybacks, #DividendPolicy","jir_key_figures":"Dividend per share: 20 yen00 sen\nTotal dividends: 832 million yen\nRecord date: September 30, 2026","jir_meta_title":"Shin Nippon Biomedical Laboratories, Ltd. - Notice Regarding Distribution of Surplus (Interim Dividend)\uff5c2026-11-10","jir_meta_description":"The interim dividend resolved today is 20 yen per share, with total dividends of 832 million yen. Record date: September 30, 2026. Payment date: November 30, 2026. The interim dividend for the fiscal year ending March 2027 is planned at the same amount.","jir_og_title":"Shin Nippon Biomedical Laboratories, Ltd. - Announcement of Interim Dividend Decision","jir_og_description":"Interim dividend of 20 yen per share, total dividends 832 million yen. Confirms record date, payment date, and future dividend policy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17048,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"dividend","footnotes":""},"sector":[],"importance":[],"class_list":["post-145948","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n